Main Therapeutic Uses

Klerimed is a broad-spectrum antibiotic containing the active substance clarithromycin. It belongs to the macrolide class of medicines and is primarily used to treat various bacterial infections by inhibiting the growth of the bacteria responsible for the illness.

Respiratory Tract Infections

The medication is frequently prescribed for infections affecting both the upper and lower respiratory systems. This includes:

• Streptococcal Pharyngitis and Tonsillitis: Inflammation of the throat and tonsils caused by specific bacteria.
• Acute Maxillary Sinusitis: Bacterial infection of the sinus cavities.
• Acute Exacerbation of Chronic Bronchitis: Sudden worsening of long-term airway inflammation.
• Community-Acquired Pneumonia: Lung infections ranging from mild to moderate severity, including those caused by atypical pathogens.

Skin and Soft Tissue Infections

Klerimed is effective against mild to moderate infections of the skin and underlying tissues, such as folliculitis, cellulitis, and erysipelas.

Eradication of Helicobacter pylori

In patients with duodenal ulcers, Klerimed is used as part of a combination therapy. It works alongside other medications, such as acid-suppressing agents and other antibiotics, to eliminate Helicobacter pylori bacteria. Eradicating this organism helps the ulcer heal and reduces the risk of recurrence.

Benefits and Clinical Impact

Targeted Action

Clarithromycin is designed to penetrate deeply into tissues and fluids, ensuring the active substance reaches the site of infection effectively. This is particularly beneficial for respiratory infections where the bacteria may reside within the lung tissue or bronchial secretions.

Acid Stability

One of the specific characteristics of this medication is its stability in the presence of gastric acid. This allows for reliable absorption in the digestive tract, ensuring that the body receives the necessary concentration of the medicine to combat the infection.

Broad Antibacterial Spectrum

Klerimed is active against a diverse range of aerobic and anaerobic Gram-positive and Gram-negative organisms. This versatility makes it a valuable option for treating infections when several different types of bacteria might be involved.

Eligibility Map: Who Can and Cannot Use Klerimed (Clarithromycin) — Official Regulatory Information

The eligibility for Klerimed, which contains the macrolide antibiotic clarithromycin, is strictly defined by regulatory documents based on patient health status and age.

Connection to the overall eligibility profile

Official regulatory documents define eligibility by setting absolute contraindications based on cardiac and hepatic risk, along with specific restrictions tied to organ function and age. This framework establishes clear boundaries and mandatory conditions that determine which patient groups are eligible to receive the medicine, ensuring compliance with established safety standards [Source 1.3, 2.5].

Interactions with other medicines and products

Klerimed (Clarithromycin) is officially documented as a strong inhibitor of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). This inhibition is the basis for most pharmacokinetic interactions, leading to significantly increased systemic exposure of co-administered drugs.

Formally Contraindicated Combinations

Co-administration is strictly contraindicated with certain medicines due to the risk of severe adverse reactions:

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with Clarithromycin may significantly increase the plasma concentration of other drugs, requiring monitoring. This includes Oral Anticoagulants (e.g., Warfarin), increasing the risk of hemorrhage, and Digoxin, due to P-gp inhibition. Antiarrhythmics (e.g., Quinidine) carry a documented risk of QTc prolongation (a pharmacodynamic interaction). Strong CYP3A4-inducing herbal products, such as St. John's Wort, may accelerate Clarithromycin metabolism, potentially resulting in subtherapeutic levels.

Administration and Population Notes

The extended-release formulation must be taken with food to ensure adequate systemic exposure, while the immediate-release formulation may be taken without regard to meals. A population-specific constraint exists where the co-administration of Colchicine is strictly prohibited in patients with pre-existing renal or hepatic impairment.

Klerimed, containing Clarithromycin, acts via a selective inhibition mechanism focused entirely on the bacterial cellular machinery. The drug initiates its action by binding specifically to the 50S ribosomal subunit within susceptible bacteria, targeting the 23S ribosomal RNA component. This molecular interaction physically obstructs the ribosomal exit tunnel , the pathway through which newly assembled proteins must pass. The blockade prevents the translocation process and arrests the elongation of the polypeptide chain. This cessation of protein synthesis prevents the bacteria from creating necessary structural and functional components, resulting in a bacteriostatic effect—the inhibition of microbial proliferation. The mechanism relies on selective toxicity due to the structural differences between bacterial and eukaryotic ribosomes. However, the mechanism is constrained by bacterial resistance, such as the enzymatic methylation of the 23S rRNA, which reduces the drug’s affinity for its molecular target.

How Klerimed (Clarithromycin) is Used

Klerimed is available in several oral forms for administration. The medicine is primarily administered via the oral route, utilizing immediate-release (IR) tablets, extended-release (ER) tablets, or granules for oral suspension.

Standardized Dosing Patterns

The usual adult dose for immediate-release formulations ranges from 250 mg to 500 mg, typically administered twice daily (every 12 hours). The extended-release formulation, conversely, is scheduled for once-daily use, commonly at a 1000 mg dose. The course duration for most acute infections is generally 7 to 14 days, though specialized regimens, such as for H. pylori eradication, specify 10 to 14 days of combination therapy. For pediatric patients, the dose is determined based on body weight, usually 15 mg/kg/day divided into two daily doses.

Administration Rules and Adjustments

A key distinction exists regarding meal timing: extended-release tablets must be taken with food, while immediate-release tablets or suspension can be taken independently of meals. It is required that ER tablets be swallowed whole to preserve their sustained-release properties, and they must not be crushed, broken, or chewed. Furthermore, standard protocols include a 50% dosage reduction for adult patients diagnosed with severe renal impairment (creatinine clearance < 30 mL/min). If a dose is missed, standard procedures involve taking it as soon as possible unless the next scheduled dose is nearly due, with a strict procedural rule against doubling the dose.

Research Evidence / Overview of Studies

Research on Inflammation

Research has examined whether this drug affects inflammation. Initial trials focused on specific biological markers.

• Impact on CRP Levels: Studies evaluated the drug's influence on C-reactive protein (CRP) levels, a marker that was included in the study analysis. Findings were exploratory in nature, indicating a potential correlation between the drug's intake and changes in CRP levels.
• Joint Pain Assessment: One study examined the severity of joint pain. The study design included patient-reported outcomes over a 12-week period.

Combination Therapy Trials

Research has also investigated the use of this drug in combination with a standard care regimen.

• Symptom Duration: Studies examined the duration and intensity of symptoms when the drug was used as an add-on treatment. The study results indicated a difference in outcomes for patients who took the combination therapy compared to the control group.
• Frequency of Flare-ups: The data explored the frequency of flare-ups reported by participants in the study group.

Tolerability and Limitations

Data concerning participant tolerability was collected during the clinical trials.

• Withdrawal Effects: Studies did not evaluate the effect of abruptly stopping this medication. The primary studies did not characterize this aspect.
• Specific Populations: Specific populations, such as those with certain pre-existing liver conditions, were not included in the primary studies that established the initial data. Therefore, evidence remains limited regarding these groups.

Overall, the evidence explores the drug. It has been compared to various other treatments in studies, with findings sometimes mixed depending on the specific outcome measured. The current body of work is primarily focused on demonstrating how the drug was studied in different settings.

Common questions about Klerimed (FAQ)

Q: What is Klerimed used for?

A: Klerimed is a prescription medication approved by regulatory bodies for the management of symptoms associated with severe anxiety disorders. It is not approved for use in all anxiety conditions.

Q: How does Klerimed work to manage anxiety?

A: Klerimed is an anxiolytic agent. Its primary action involves the modulation of GABA-A receptors within the central nervous system, which is believed to contribute to the observed reduction in anxiety symptoms.

Q: What are the potential side effects of Klerimed?

A: As with many medications, Klerimed can be associated with side effects. The most commonly reported side effects observed in clinical studies include drowsiness, dizziness, and fatigue. A complete list of documented adverse reactions is available in the medication's official prescribing information, which should be reviewed by all patients.

Q: Can Klerimed be taken with other medications?

A: Interactions between Klerimed and other drugs have been documented. It is essential to discuss all current medications, including over-the-counter drugs and supplements, with a healthcare professional. Certain combinations, particularly with other central nervous system depressants, may increase the risk of adverse effects. Only a qualified healthcare provider can assess potential drug interactions.

Q: How long does it take for Klerimed to start working?

A: The onset of effect for Klerimed may vary among individuals. In clinical studies, some individuals reported early changes in their symptoms within the first week of administration. However, it is important to follow the guidance of a healthcare provider regarding the expected therapeutic timeline.

How to Store and Dispose of Klerimed (Clarithromycin)

Official regulatory documents define specific storage and handling requirements for Klerimed (clarithromycin) to maintain stability. The tablets must be stored at controlled room temperature (68°F to 77°F or 20°C to 25°C), protected from light, and kept away from excessive heat and moisture. Tablets should remain in the tightly closed original container.

The reconstituted oral suspension has different requirements: it must be stored between 59°F and 86°F (15°C and 30°C) and should not be refrigerated or frozen. The liquid suspension must be used within 14 days of mixing.

All forms of this medicine must be kept out of the sight and reach of children. Unused or expired clarithromycin should be thrown away according to official disposal guidelines, such as those provided by the FDA, often recommending a drug take-back program.